Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.2%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,410,000 shares, an increase of 5.2% from the January 15th total of 1,340,000 shares. Approximately 4.6% of the shares of the stock are sold short. Based on an average daily volume of 419,500 shares, the days-to-cover ratio is presently 3.4 days.

Hedge Funds Weigh In On iTeos Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ITOS. The Manufacturers Life Insurance Company boosted its position in shares of iTeos Therapeutics by 6.6% in the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after acquiring an additional 690 shares during the period. Creative Planning raised its stake in iTeos Therapeutics by 6.5% in the third quarter. Creative Planning now owns 19,636 shares of the company’s stock valued at $200,000 after purchasing an additional 1,196 shares in the last quarter. SG Americas Securities LLC raised its stake in iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after purchasing an additional 1,508 shares in the last quarter. nVerses Capital LLC raised its stake in iTeos Therapeutics by 212.5% in the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in iTeos Therapeutics by 16.9% in the fourth quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock valued at $128,000 after purchasing an additional 2,402 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Price Performance

Shares of ITOS stock opened at $7.40 on Tuesday. The firm has a 50-day moving average of $7.64 and a 200-day moving average of $10.20. The company has a market cap of $270.32 million, a P/E ratio of -2.35 and a beta of 1.38. iTeos Therapeutics has a one year low of $7.06 and a one year high of $18.75.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Wedbush reissued an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Friday, January 10th. Wells Fargo & Company reduced their target price on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a report on Thursday, January 16th.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.